About 12 percent of Americans have tried a GLP-1, RAND reports
We will further look into this and explore how we can help patients with addiction, potentially with GLP-1, Lange said, also adding that it has to be addressed in a scientific, and obviously also from a regulatory perspective, very rigorous way so we can really see the potential impact of GLP-1 in that space. However, in response to questions from Biospace, a Novo spokesperson said that Lange was referring to the already ongoing work studying semaglutide on liver damage and alcohol use in its phase 2 trial, and that the company has no plans to study the drug in broader addiction indications
We identified three prior studies that, at the time, further suggested a possible link between GLP-1 and AUD
L.PennM
These come with prescriber oversight, standardized manufacturing under pharmacy regulations, and dosing guidance